Ibalizumab Active in Multidrug Resistant HIV-1 Infection
THURSDAY, Aug. 16, 2018 -- Ibalizumab has antiviral activity among patients with multidrug resistant (MDR) HIV-1 infection, according to a study published in the Aug. 16 issue of the New England Journal of Medicine.
Brinda Emu, M.D., from the Yale School of Medicine in New Haven, Conn., and colleagues enrolled 40 adults with MDR HIV-1 infection. A 2,000 mg loading dose of ibalizumab was infused into patients after a seven-day control period in which patients continued to receive their current therapy; the viral load was quantified seven days later. Patients received 800 mg of ibalizumab every 14 days through week 25 of the study.
Thirty-one patients completed the study. The researchers found that 83 percent of the 40 patients in the intention-to-treat population had a decrease in viral load of at least 0.5 log10 copies per milliliter from baseline, with a mean viral-load decrease of 1.1 log10 copies per milliliter. Patients who received ibalizumab plus an optimized background regimen had a mean decrease of 1.6 log10 copies per milliliter from baseline; 43 percent of the patients had a viral load <50 copies per milliliter and 50 percent had a viral load of <200 copies per milliliter. Nine of the 10 patients who had virologic failure or rebound had a lower degree of susceptibility to ibalizumab than at baseline on in vitro testing.
"In patients with MDR HIV-1 infection who had advanced disease and limited treatment options, ibalizumab had significant antiviral activity during a 25-week study," the authors write.
The study was funded in part by TaiMed Biologics, the manufacturer of ibalizumab.
© 2020 HealthDay. All rights reserved.
Posted: August 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.